Moxifloxacin for the Treatment of Patients with Complicated Intra-abdominal Infections (the AIDA Study)

REFERENCES

• Berger D, Buttenschoen K. Management of abdominal sep-sis. Langenbecks Arch Surg 1998; 383: 35–43.
   PubMed Web of Science ®Google Scholar
• Bruch HP, Woltmann A, Eckmann C. Surgical management of peritonitis and sepsis. Zentralbl Chir 1999; 124: 176–180.
   PubMed Web of Science ®Google Scholar
• Buijk SE, Bruining HA. Future directions in the management of tertiary peritonitis. Intensive Care Med 2002; 28: 1024–1029.
   PubMed Web of Science ®Google Scholar
• Marshall JC, Innes M. Intensive care unit management of infra-abdominal infection. Crit Care Med 2003; 31: 2228–2237.
   PubMed Web of Science ®Google Scholar
• Roehrborn A, Thomas L, Potreck O, Ebener C, Ohmann C, Goretzki PE, et al. The microbiology of postoperative peri-tonitis. Clin Infect Dis 2001; 33: 1513–1519.
   PubMed Web of Science ®Google Scholar
• Blot S, De Waele JJ. Critical issues in the clinical management of complicated intra-abdominal infections. Drugs 2005; 65: 1611–1620.
   PubMed Web of Science ®Google Scholar
• Stass H, Rink AD, Delesen H, Kubitza D, Vestweber KH. Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis. J Antimicrob Chemother. 2006; 58: 693–696.
   PubMed Web of Science ®Google Scholar
• Rink AD, Stass H, Delesen H, Kubitza D, Vestweber KH. Pharmacokinetics and tissue penetration of moxifloxacin in inter-vention therapy for intra-abdominal abscess. Clin Drug Invest 2008; 28: 71–79.
   PubMed Web of Science ®Google Scholar
• Solomkin JS, Mazuski JE, Baron EJ, Sawyer RG, Nathens AB, DiPiro JT, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37: 997–1005.
   PubMed Web of Science ®Google Scholar
• AVELOX° tablets UK prescribing information, Bayer Schering Pharma, November 2007.
   Google Scholar
• Ackermann G, Schaumann R, Pless B, Claros MC, Gold-stein EJC, Rodtoff AC. Comparative activity of moxifloxacin in vitro against obligate anaerobic bacteria. Eur J Clin Microbiol In-fect Dis 2000; 19: 228–232.
   PubMed Web of Science ®Google Scholar
• Edmiston CE, Krepel CJ, Seabrook GR, Somberg LR, Na-keeb A, Cambria RA, et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother 2004; 48: 1012-1016.
   Google Scholar
• Muller M, Stass H, Brunner M, Möller JG, Lackner E, Eichler HG. Penetration of moxifloxacin into peripheral com-partments in humans. Antimicrob Agents Chemother 1999; 43: 2345–2349.
   PubMed Web of Science ®Google Scholar
• Wirtz M, Kleeff J, Swoboda S, Halaceli I, Geiss HK, Hoppe-Tichy T, et al. Moxifloxacin penetration into human gastrointestinal tissues. J Antimicrob Chemother 2004; 53: 875–877.
   PubMed Web of Science ®Google Scholar
• Mayer-Bartschmid A, Schuhmacher J, Dörlemann S, Haas A. Determination of PK/PD parameters of moxifloxacin against Bacteroides thetaiotaomicron in vitro at static and at varying drug concentrations. 17th European Congress of Clinical Micro-biology and Infectious Diseases and 25th International Congress of Chemotherapy, Munich, Germany, 31 March-3 April 2007, poster 1651.
   Google Scholar
• Glenschek-Sieberth M, Merfort K, Obertegger S, Kne2evie I, Endermann R. In vivo efficacy of moxifloxacin monotherapy against clinical isolates of B. fragilis with intermediate suscepti-bility. European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, 19-22 April 2008, poster 1065.
   Google Scholar
• Glenschek-Sieberth M, Merfort K, Obertegger S. A new animal model for severe complications of intra-abdominal infections: chronic uterus infections caused by B. fragilis. European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, 19-22 April 2008, poster 1932.
   Google Scholar
• Thadepalli H, Chuah SK, Gollapudi S. Therapeutic effi-cacy of moxifloxacin, a new quinolone, in the treatment of ex-perimental intra-abdominal abscesses induced by Bacteroides fragilis in mice. Chemotherapy 2004; 50: 76–80.
   PubMed Web of Science ®Google Scholar
• Glenschek-Sieberth M, Mayer-Bartschmid A, Merfort K, Obertegger S, Hartke S, Haas M. In vivo and in vitro efficacy of moxifloxacin monotherapy against B. fragilis mutant strains with elevated MICs. 47th Annual Interscience Conference on Anti-microbial Agents and Chemotherapy, 17-20 September 2007, Chicago, USA, poster A-21.
   Google Scholar
• Malangoni MA, Song J, Herrington J, Choudhri S, Pertel P. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treat-ment of complicated intra-abdominal infections. Ann Surg 2006; 244: 20–11.
   Google Scholar
• Solomkin JS, Zhao Y-P, Chen M-J, et al. Moxifloxacin IV is an effective empirical therapy for complicated intra-abdominal infections (cIAIs) - the DRAGON study. 16th Asian Surgical Bi-ennial Congress, 19-22 October 2007, Beijing, China.
   Google Scholar
• Lippert H, Weiss G, Choudhri SH, Herrington J, Briel-mann J-M. Clinical and bacteriological efficacy of sequential in-travenous (IV) to oral (PO) moxifloxacin in patients with complicated intra-abdominal Infections (cIAI) due to Enterobac-teriaceae. 20th European Congress on Surgical Infections, Frank-furt, Germany, 17–19 May 2007.
   Google Scholar
• Lippert H, Weiss G, Malangoni M, et al. Bacteriological efficacy of sequential intravenous (IV) to oral (PO) moxifloxacin for polymicrobial complicated intra-abdominal infections (cIAI). 20th European Congress on Surgical Infections, Frankfurt, Germany, 17–19 May 2007, abstract.
   Google Scholar
• Avelox IV US Prescribing Information, Bayer HealthCare and Schering-Plough, 2007.
   Google Scholar
• Cisneros RL, Onderkonk AB. Antimicrobial efficacy Testing of moxifloxacin during the peritonitis and abscess formation stages of intra-abdominal sepsis: a controlled trial in the rat model. Curr Ther Res Clin Exp 2002; 63: 821–827.
   Web of Science ®Google Scholar
• Barie P, Vogel ST, Dellinger E, Rotstein O, Solomkin JS, Yang JY, et al. A randomized, double-blind clinical trial compa-ring cefipime plus metronidazole with imipenem-cilastatin in the treatment of complicated intraabdominal infections. Arch Surg 1997; 132: 1294–1302.
   PubMed Web of Science ®Google Scholar
• Dupont H, Carbon C, Carlet J. Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in the treatment of severe, generalized peri-tonitis: a multicenter randomized controlled trial. Antimicrob Agents Chemother 2000; 44: 2028–2033.
   PubMed Web of Science ®Google Scholar
• Solomkin J, Yellin A, Rotstein O, Christou NV, Dellinger EP, Tellado JM, et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 2003; 237: 235–245.
   PubMed Web of Science ®Google Scholar
• Goldstein JC, Snydman DR. Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy. J Antimicrob Chemother 2004; 53 (Suppl. 2): ii29-36.
   Google Scholar